Johnson & Johnson — Stelara (ustekinumab) $JNJ

for Pediatric Crohn's disease (ages 2 and older)

sBLA

FDA approved ustekinumab (Stelara) for patients aged two years and older with moderately to severely active Crohn's disease — pediatric label expansion of an already-marketed biologic.